Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 152Neoplasms 108Carcinoma, Non-Small-Cell Lung 83Colorectal Neoplasms 81Prostatic Neoplasms 80Lung Neoplasms 71Leukemia, Myeloid, Acute 48Carcinoma, Hepatocellular 48Pancreatic Neoplasms 45Neoplasm Metastasis 39Multiple Myeloma 37Recurrence 34Triple Negative Breast Neoplasms 29Squamous Cell Carcinoma of Head and Neck 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Melanoma 27Glioblastoma 27Head and Neck Neoplasms 25Brain Neoplasms 25Uterine Cervical Neoplasms 24Stomach Neoplasms 24Rectal Neoplasms 24Ovarian Neoplasms 24Small Cell Lung Carcinoma 22Carcinoma, Renal Cell 20Lymphoma, B-Cell 19Lymphoma, Follicular 18Lymphoma 18Endometrial Neoplasms 18Glioma 17

Interventions

trifluridine tipiracil drug combination 1tipiracil 1regorafenib 1Trifluridine 1Tablets 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × HER2 IHC3+ Advanced Colorectal Cancer × 90 days × Clear all
NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
142 enrolled
Gastrointestinal

HER2 IHC3+ Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡